Name: 글로벌 시장 동향
SKU: PH7212
Availability: InStock

보고서 요약(국문)

개요
전 세계 구순포진 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
구순포진은 입술, 잇몸 또는 목에 작고 아픈 물집이 생기는 구강 질환입니다. 이 물집은 헤르페스 심플렉스 바이러스에 의해 유발되는데, 이 바이러스는 흔하고 전염성이 매우 높은 바이러스로, 미국에서는 20세 이전에 대부분의 사람들이 감염됩니다.
심한 구순포진의 경우, 아시클로비르, 팜시클로비르, 발라시클로비르와 같은 항바이러스제가 처방될 수 있습니다. 이러한 항바이러스제는 증상이 처음 나타날 때(예: 입 주변에 따끔거림이 느껴질 때) 그리고 물집이 생기기 전에 복용하면 효과적입니다.

시장 동향: 성장 동력 및 제약 요인
증가하는 유병률
구순포진의 유병률 증가는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 존스 홉킨스 대학에 따르면 미국 성인의 50~80%가 구강 헤르페스(HSV-1) 바이러스를 보유하고 있으며, 이 바이러스는 입 안이나 입 주변에 물집을 유발합니다.
HSV-1 또는 HSV-2에 의해 발생하는 생식기 헤르페스는 미국에서 14세에서 49세 사이의 성인 6명 중 1명꼴로 발생합니다. 또한, 세계보건기구(WHO)는 전 세계 인구의 약 67%가 구강 헤르페스(HSV-1)에 감염되었고, 약 11%가 생식기 헤르페스(HSV-2)에 감염되었다고 추정합니다. 더불어, 구순포진의 가장 흔한 원인인 단순포진 바이러스 1형은 전 세계적으로 37억 명에게 존재하는 것으로 추산됩니다.

또한, 연구 활동 증가, 인식 제고 및 시장 개발은 예측 기간 동안 전 세계 구순포진 시장 성장에 기여할 것으로 예상됩니다.
엄격한 규제 기관
FDA 및 EMA를 비롯한 신약 승인 및 상용화를 통제하는 엄격한 규제 기관의 존재는 예측 기간 동안 전 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 치료 선택의 폭 부족, 낮은 투자 및 자금 조달, 높은 신약 개발 비용 또한 예측 기간 동안 전 세계 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 구순포진 치료 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
아시클로비르 시장 주도 예상
아시클로비르의 제품 출시 및 승인 증가로 인해 해당 부문 시장 성장이 촉진되어 예측 기간 동안 전 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2022년 10월 Camber Pharmaceuticals는 아시클로비르 경구 현탁액을 출시하여 기존 포트폴리오를 확장했습니다. 아시클로비르 경구 현탁액은 헤르페스 바이러스 치료에 사용되는 인공 뉴클레오사이드 유사체입니다. 또한, 2020년 11월, 암닐 파마슈티컬스(Amneal Pharmaceuticals, Inc.)는 미국 식품의약국(FDA)으로부터 아시클로비르 크림 5%에 대한 신약 간이 허가 신청(ANDA)을 승인받았습니다. 아시클로비르 크림 5%는 면역력이 정상인 성인 및 12세 이상 청소년의 재발성 구순포진(단순포진) 치료에 사용되는 조비락스(Zovirax)의 제네릭 버전입니다.
지역 분석
북미 지역이 세계 시장을 주도할 것으로 예상됨
북미 지역에서 구순포진 치료제에 대한 제품 승인 및 임상 연구가 증가함에 따라, 예측 기간 동안 북미 지역이 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2020년 12월 EPI Health, LLC는 면역력이 정상인 사람의 재발성 구순포진 치료를 위한 시타빅(아시클로비르) 구강정의 FDA 신약 허가 신청(NDA) 승인을 받았습니다.
또한, 바이엘은 미국에서 면역력이 정상인 성인의 구순포진 치료를 위해 시타빅(아시클로비르) 50mg 점막 부착성 구강정과 위약을 비교하는 3상 무작위 배정, 다기관, 이중맹검, 자체 개시 치료 연구를 시작했습니다. 더 나아가, 이 지역에서 구순포진의 유병률과 인식이 증가함에 따라 예측 기간 동안 지역 시장 성장이 촉진될 것으로 예상됩니다.

시장 세분화
약품별
• 아시클로비르
• 발라시클로비르
• 팜시클로비르
• 도코사놀
• 기타
투여 경로별
• 국소
• 경구
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2021년 8월, 성인의 재발성 구순포진(입술포진) 치료에 권장되는 제레세(아시클로비르 및 히드로코르티손) 크림이 FDA의 신약 승인을 받았습니다.

• 2021년 2월, FDA는 이노큐티스 홀딩스(Innocutis Holdings, LLC)로부터 구순포진 치료제 아시클로비르 크림 5%에 대한 약식 신약 허가 신청(ANDA)을 접수했습니다.
• 2020년 10월, 마루호(Maruho Co., Ltd.)는 재발성 구순포진 치료를 위한 국소 도포제 MRK-003의 3상 임상 연구에서 유망한 결과를 발표했습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 테바 제약(Teva Pharmaceuticals Industries Ltd), 칼스배드 테크(Carlsbad Tech), 노바티스(Novartis AG), 이노큐티스 홀딩스(Innocutis Holdings, LLC), 프레제니우스 카비(Fresenius Kabi AG), 아포텍스(Apotex Inc.), GSK(GSK plc), 애브비(Abbvie Inc.), 마일란(Mylan N.V.) 등이 있습니다.

보고서 구매 이유

• 약물, 투여 경로, 유통 채널 및 지역별 글로벌 구순포진 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위함입니다. • 모든 세그먼트를 포함한 구순포진 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공

글로벌 구순포진 치료 시장 보고서는 약 61개의 표, 69개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Herpes Labialis Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Herpes labialis or oral herpes is a condition of the mouth region that generates little, sore blisters to grow on the lips, gums, or throat. These blisters are induced by the herpes simplex virus, a typical and highly transmissible virus that contaminates a majority of individuals in the U.S. by the time they attain the age of 20.
For extreme cases of herpes labialis, antiviral tablets may be suggested including acyclovir, famciclovir, and valacyclovir. These antiviral drugs are additionally efficacious if they are dosed as shortly as manifestation first presents (e.g. when tingling is felt around the mouth) and before the blisters first occur.
Market Dynamics: Drivers & Restraints
Growing Prevalence
The growing prevalence of Herpes Labialis is expected to boost the global market growth during the forecast period. For instance, according to Johns Hopkins Fifty to eighty percent of American adults hold oral herpes (HSV-1), which generates cold sores or fever blisters in or near the mouth.
Genital herpes, induced by HSV-1 or HSV-2, influences one among six individuals in the U.S. aged 14 to 49. Moreover, the WHO assesses that nearly 67% of the globe's inhabitants contain oral herpes or HSV-1 and that almost 11% have genital herpes, or HSV-2. Also, the herpes simplex virus type 1, which is the highly dominant reason for herpes labialis, is considered to be current in 3.7 billion individuals globally.
Furthermore, the increasing research activities, growing awareness and market developments are also expected to contribute to the global Herpes Labialis market growth during the forecast period.
Stringent Regulatory Authorities
The presence of stringent regulatory authorities controlling new drug approvals and commercialization including the FDA and EMA among other is expected to hamper the global market growth during the forecast period. Furthermore, the low treatment choices, low investments, fundings and high drug development costs are also expected to hamper the global market growth during the forecast period.
Segment Analysis
The global herpes labialis treatment market is segmented based on drug, route of administration, distribution channel and region.
Acyclovir is Expected to Dominate Market
Owing to the increasing product introductions and approvals for Acyclovir is expected to boost the segment market growth, dominating the global market during the forecast period. For instance, in October 2022, Camber Pharmaceuticals introduced Acyclovir Oral Suspension and extended its current portfolio. Acyclovir Oral Suspension is an artificial nucleoside analog functional in herpes virus treatment. Moreover, in November 2020, Amneal Pharmaceuticals, Inc. obtained authorization for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax to treat recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increase in product approvals and clinical investigations for herpes labialis treatment in North America, the region is expected to dominate the global market throughout the forecast period. For instance, in December 2020, EPI Health, LLC obtained an FDA New Drug Application (NDA) authorization for Sitavig (acyclovir) Buccal Tablet for the treatment of recurrent herpes labialis in immunocompetent individuals.
Moreover, Bayer has begun a Phase 3 randomized, Multi-Center, Double-Blinded, Self-Initiated, Treatment Study Comparing Sitavig (Acyclovir) 50 mg Mucoadhesive Buccal Tablet to Placebo in the treatment of herpes labialis in immunocompetent adults in United States. Furthermore, the growing prevalence and awareness in this region is also boosting the regional market growth during the forecast period.
Market Segmentation
By Drug
• Acyclovir
• Valacyclovir
• Famciclovir
• Docosanol
• Others
By Route of Administration
• Topical
• Oral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In August 2021, the Xerese (acyclovir and hydrocortisone) cream (recommended for the treatment of recurrent herpes labialis (cold sores) in adults) obtained FDA authorization for a new drug application.
• In February 2021, FDA had received the Abbreviated New Drug Application (ANDA) from Innocutis Holdings, LLC for its Acyclovir Cream 5% to treat herpes labialis.
• In October 2020, Maruho Co., Ltd. reported promising conclusions a phase 3 clinical investigation of its topical medication, MRK-003, fto treat recurrent herpes labialis.
Competitive Landscape
The major global players in the market include Teva Pharmaceuticals Industries Ltd, Carlsbad Tech, Novartis AG, Innocutis Holdings, LLC, Fresenius Kabi AG, Apotex Inc., GSK plc, Abbvie Inc., and Mylan N.V. among others.
Why Purchase the Report?
• To visualize the global herpes labialis treatment market segmentation based on drug, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of herpes labialis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global herpes labialis treatment market report would provide approximately 61 tables, 69 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
7.1.2. Market Attractiveness Index, By Drug
7.2. Acyclovir*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Valacyclovir
7.4. Famciclovir
7.5. Docosanol
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Topical*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
8.4. Other
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceuticals Industries Ltd*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Carlsbad Tech
12.3. Novartis AG
12.4. Innocutis Holdings, LLC
12.5. Fresenius Kabi AG, Inc.
12.6. Apotex Inc.
12.7. Mylan N.V.
12.8. AbbVie Inc.
12.9. GSK plc
12.10. Viatris Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Teva Pharmaceuticals Industries Ltd, 4.	Key Developments, Carlsbad Tech, Novartis AG, Innocutis Holdings, LLC, Fresenius Kabi AG, Inc., Apotex Inc., Mylan N.V., AbbVie Inc., GSK plc, Viatris Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Herpes Labialis Treatment Market Value, By Drug, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Herpes Labialis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Herpes Labialis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Herpes Labialis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Herpes Labialis Treatment Market Value, By Drug, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 7 Global Herpes Labialis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Herpes Labialis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Herpes Labialis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Herpes Labialis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 14 North America Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Herpes Labialis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 18 South America Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Herpes Labialis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 22 Europe Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Herpes Labialis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Herpes Labialis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Herpes Labialis Treatment Market Value, By Drug, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Herpes Labialis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Herpes Labialis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Teva Pharmaceuticals Industries Ltd: Overview

Table 33 Teva Pharmaceuticals Industries Ltd: Product Portfolio

Table 34 Teva Pharmaceuticals Industries Ltd: Key Developments

Table 35 Carlsbad Tech: Overview

Table 36 Carlsbad Tech: Product Portfolio

Table 37 Carlsbad Tech: Key Developments

Table 38 Novartis AG: Overview

Table 39 Novartis AG: Product Portfolio

Table 40 Novartis AG: Key Developments

Table 41 Innocutis Holdings, LLC: Overview

Table 42 Innocutis Holdings, LLC: Product Portfolio

Table 43 Innocutis Holdings, LLC: Key Developments

Table 44 Fresenius Kabi AG, Inc.: Overview

Table 45 Fresenius Kabi AG, Inc.: Product Portfolio

Table 46 Fresenius Kabi AG, Inc.: Key Developments

Table 47 Apotex Inc.: Overview

Table 48 Apotex Inc.: Product Portfolio

Table 49 Apotex Inc.: Key Developments

Table 50 Mylan N.V.: Overview

Table 51 Mylan N.V.: Product Portfolio

Table 52 Mylan N.V.: Key Developments

Table 53 AbbVie Inc.: Overview

Table 54 AbbVie Inc.: Product Portfolio

Table 55 AbbVie Inc.: Key Developments

Table 56 GSK plc: Overview

Table 57 GSK plc: Product Portfolio

Table 58 GSK plc: Key Developments

Table 59 Viatris Inc.: Overview

Table 60 Viatris Inc.: Product Portfolio

Table 61 Viatris Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 3 Global Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Herpes Labialis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Herpes Labialis Treatment Market Y-o-Y Growth, By Drug, 2022-2030 (%)

Figure 7 Acyclovir Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Valacyclovir Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Famciclovir Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Docosanol Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Others Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Herpes Labialis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Topical Route of Administration in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Oral Route of Administration in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Other Route of Administration in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Herpes Labialis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Herpes Labialis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 28 North America Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Herpes Labialis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 South America Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 33 South America Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Herpes Labialis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 38 Europe Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Herpes Labialis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 43 Asia-Pacific Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Herpes Labialis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Herpes Labialis Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Herpes Labialis Treatment Market Share, By Drug, 2022 & 2030 (%)

Figure 48 Middle East & Africa Herpes Labialis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Herpes Labialis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Teva Pharmaceuticals Industries Ltd: Financials

Figure 51 Carlsbad Tech: Financials

Figure 52 Novartis AG: Financials

Figure 53 Innocutis Holdings, LLC: Financials

Figure 54 Fresenius Kabi AG, Inc.: Financials

Figure 55 Apotex Inc.: Financials

Figure 56 Mylan N.V.: Financials

Figure 57 AbbVie Inc.: Financials

Figure 58 GSK plc: Financials

Figure 59 Viatris Inc.: Financials

세계 구순포진 치료 시장 – 2023-2030

Global Herpes Labialis Treatment Market - 2023-2030